Halozyme Therapeutics, Inc. HALO
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About HALO
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Halozyme Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing and commercializing drug delivery technologies and specialty therapeutics. The company operates primarily within the biopharmaceutical and oncology sectors, with its core business centered on its proprietary ENHANZE drug delivery platform, which enables subcutaneous administration of injectable biologics and therapeutics that are traditionally delivered intravenously. Halozyme generates revenue through product sales, licensing agreements, royalties, and collaborative partnerships with large pharmaceutical companies.
The company’s principal revenue drivers include royalties and milestone payments tied to partnered products using the ENHANZE platform, as well as sales from proprietary products. Halozyme serves global pharmaceutical manufacturers, healthcare providers, and patients requiring biologic therapies across oncology, immunology, hematology, and rare disease indications. The company was founded in 1998 and evolved from an early-stage enzyme technology developer into a platform-focused biotechnology company through strategic licensing arrangements and commercialization partnerships with major global drugmakers.
Business Operations
Halozyme’s operations are primarily organized around its proprietary ENHANZE technology platform and related therapeutic assets. The company’s recombinant human hyaluronidase enzyme technology facilitates rapid subcutaneous delivery of large-volume injectable drugs, improving convenience and reducing administration time compared with intravenous infusion. Revenue is generated through licensing agreements, upfront payments, milestone payments, royalties on partnered commercial products, and product sales associated with internally developed therapies.
Halozyme maintains operations primarily in the United States, while its partnered products have broad international commercial reach through collaborations with global pharmaceutical companies including Roche, Bristol Myers Squibb, Johnson & Johnson, Pfizer, AbbVie, argenx, and Takeda. The company controls intellectual property related to recombinant hyaluronidase technology and associated delivery systems. Its partnered products span multiple therapeutic areas, including oncology and autoimmune diseases, with several approved medicines utilizing the ENHANZE platform in major global markets.
Strategic Position & Investments
Halozyme’s strategic direction has focused on expanding adoption of the ENHANZE platform through additional licensing agreements, lifecycle management opportunities for biologic drugs, and long-term royalty-generating partnerships. The company has emphasized capital-efficient growth by leveraging external commercialization partners rather than building large-scale global sales infrastructure independently. This strategy has positioned Halozyme as a key infrastructure provider within biologic drug delivery rather than a traditional fully integrated pharmaceutical company.
The company has pursued acquisitions and portfolio optimization to strengthen its technology and commercial capabilities. A notable transaction included the acquisition of Antares Pharma, Inc. in 2022, which expanded Halozyme’s drug-device combination and self-injection technology capabilities. Halozyme continues to invest in next-generation delivery technologies and intellectual property expansion related to subcutaneous biologic administration. Its portfolio exposure to oncology, immunology, and rare diseases aligns with broader pharmaceutical industry trends favoring patient-convenient administration methods and outpatient care models.
Geographic Footprint
Halozyme is headquartered in San Diego, California, and conducts its primary corporate and research operations in the United States. Although the company’s direct operational footprint is concentrated domestically, its commercial influence is global due to the international distribution of partnered therapies incorporating the ENHANZE platform.
Through collaborations with multinational pharmaceutical companies, Halozyme-supported products are marketed across North America, Europe, Asia-Pacific, and other international healthcare markets. The company’s royalty-based business model provides exposure to global biologic drug markets without requiring extensive direct foreign operating infrastructure. International commercialization partnerships have expanded the reach of Halozyme-enabled therapies into major pharmaceutical markets including the European Union, Japan, and other developed healthcare systems.
Leadership & Governance
Halozyme’s leadership team combines biotechnology, pharmaceutical commercialization, and medical technology experience. The company’s governance structure emphasizes long-term platform monetization, strategic partnerships, intellectual property management, and disciplined capital allocation. Public filings and investor communications have consistently highlighted management’s focus on expanding the commercial adoption of the ENHANZE platform while maintaining operational scalability.
Key executives include:
- Helen Torley, M.B. Ch.B. – President and Chief Executive Officer
- Nicole Labrosse – Chief Financial Officer
- Michael Labarre – Chief Technical Operations Officer
- Doretta Mistras – Chief Human Resources Officer
- Dr. H. Michael Shepard – Senior Vice President, Research and Development
- Jonathan Lim, M.D. – Chairman of the Board
Halozyme’s leadership strategy has centered on increasing recurring royalty streams, deepening relationships with major pharmaceutical partners, and expanding the number of approved products utilizing the company’s proprietary delivery technology.